Ero sivun ”Etanersepti” versioiden välillä
Siirry navigaatioon
Siirry hakuun
| [katsottu versio] | [katsottu versio] |
Poistettu sisältö Lisätty sisältö
Ei muokkausyhteenvetoa |
|||
| Rivi 3: | Rivi 3: | ||
==Licensed indications== |
==Licensed indications== |
||
In the USA the FDA has licenced Enbrel for : |
In the USA the FDA has licenced Enbrel for : |
||
*Moderate to Severe [[ |
*Moderate to Severe [[Nivelreuma]] (RA) (Nov 1998) |
||
*Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) (1999) |
*Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) (1999) |
||
*Psoriatic Arthritis (2002) |
*Psoriatic Arthritis (2002) |
||
Versio 15. syyskuuta 2012 kello 01.23
Enbrel on lääke joka hoitaa autoimmuunisairauksia TNF-infektoituneilla. is a drug that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. Pfizer describes in a SEC filing that the drug is used to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Sales reached record $3.3 billion in 2010.[1]
Licensed indications
In the USA the FDA has licenced Enbrel for :
- Moderate to Severe Nivelreuma (RA) (Nov 1998)
- Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) (1999)
- Psoriatic Arthritis (2002)
- Ankylosing Spondylitis (AS) (July 2003)[2]
- Moderate to Severe Plaque Psoriasis (April 2004)